Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04707469 · ClinicalTrials.gov registry record · Phase 3
Research Study to Compare Three Doses of Semaglutide Tablets Taken Once Daily in People With Type 2 Diabetes
A Phase 3 study, sponsored by Novo Nordisk A/S.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,606
- Enrollment target
NCT04707469 is a Phase 3 study that has completed, run by Novo Nordisk A/S. The registered enrollment target is 1,606 participants.
The verdict
NCT04707469, a Phase 3 study, has completed, sponsored by Novo Nordisk A/S.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,606 participants
- Enrollment target
Study Summary
This study compares three doses of once daily semaglutide tablets in people with type 2 diabetes who were previously treated with other oral anti-diabetic medicines. Participants will be initiated on the lowest starting dose of 3 mg and gradually increased until they reach the final trial dose of 14 mg, 25 mg or 50 mg once daily semaglutide tablets. The final three doses will be randomized (i.e., decided by chance). Participants will be administered one tablet per day for 68 weeks. Women cannot take part if they are pregnant, breast-feeding or planning to become pregnant during the study period. Women who can get pregnant will be checked for pregnancy via urine tests. Once daily semaglutide tablets (3 mg, 7 mg and 14 mg) are approved for the treatment of type 2 diabetes in the US, in the EU and in some other countries, under the brand name Rybelsus®.
Interventions
- DRUG Oral semaglutide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,606 participants |
| Start Date | 2021-01-15 |
| Est. Completion | 2023-03-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04707469
The ClinicalTrials.gov registry entry for NCT04707469 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,606 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Oral semaglutide is the first listed.
NCT04707469 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04707469 about?
NCT04707469 is a clinical study titled "Research Study to Compare Three Doses of Semaglutide Tablets Taken Once Daily in People With Type 2 Diabetes". This study compares three doses of once daily semaglutide tablets in people with type 2 diabetes who were previously treated with other oral anti-diabetic medicines. Participants will be initiated on the lowest starting dose of 3 mg and gradually increased until they reach the final trial dose of 14...
What is the current status of trial NCT04707469?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,606 participants. The study started on 2021-01-15. Estimated completion is 2023-03-08.
What interventions are being tested in trial NCT04707469?
The interventions under investigation include: Oral semaglutide (DRUG).
Who is sponsoring clinical trial NCT04707469?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.